Detailed price information for Design Therapeutics Inc (DSGN-Q) from The Globe and Mail including charting and trades.

Dyne Therapeutics, Inc. ( (DYN) ) has released its Q3 earnings. Here is a breakdown of the information Dyne Therapeutics, Inc. presented to its ...

Analyst Michael Ulz from Morgan Stanley reiterated a Buy rating on Dyne Therapeutics (DYN – Research Report) and keeping the price target ...

Avidity Biosciences stock surges on expansion of pipeline targeting rare genetic cardiomyopathies and improvements in siRNA ...

Investors consider Dyne Therapeutics' treatments for muscle diseases and strong cash position as a speculative Buy ...